Carmat announces the issuance of a second tranche of equity warrants within the framework of its contingent equity line with Kepler Cheuvreux
Source: Carmat
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces the issuance of a secondtranche of650,000 equity warrants within the framework of thecontingentequityline withKepler Cheuvreux.
On September27,2018, CARMAT put in place acontingentequity line contractwithKepler Cheuvreuxfor a maximum amount of €25 million for a duration of 3 years.
The firsttranche of400,000 equity warrants,issued inSeptember2018, has, to date, enabled the Company to benefitfrom €9.1 million in financing within the framework of this contract.
-
Most popular related searches
Customer comments
No comments were found for Carmat announces the issuance of a second tranche of equity warrants within the framework of its contingent equity line with Kepler Cheuvreux. Be the first to comment!